MedPage Today on MSN
Novel Drug Fails to Outperform Common Treatment in Depression and Insomnia
An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...
Personalized high-definition transcranial direct current stimulation is linked to improved outcomes in moderate-to-severe ...
A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some ...
Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI ...
A small study found a 10-week ketogenic diet was associated with a roughly 70% decrease in depression symptoms, improved well ...
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with ...
Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated ...
It is developing the medication in collaboration with a privately held peer.
Pharmaceutical Technology on MSN
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe
The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past ...
SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that results from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback